Document Classification

Section Type: RESULTS

Text: Compared with placebo, the V710 vaccine was associated with more adverse experiences during the first 14 days after vaccination (1219/3958 vaccine recipients [30. 8 % ; 95 % CI, 29. 4 % -32. 3 %] and 866/3967 placebo recipients [21. 8 % ; 95 % CI, 20. 6 % -23. 1 %], including 797 [20. 1 % ; 95 % CI, 18. 9 % -21. 4 %] and 378 [9. 5 % ; 95 % CI, 8. 6 % -10. 5 %] with injection site reactions and 66 [1. 7 % ; 95 % CI, 1. 3 % -2. 1 %] and 51 [1. 3 % ; 95 % CI, 1. 0 % -1. 7 %] with serious adverse events, respectively) and a significantly higher rate of multiorgan failure during the entire study (31 vs 17 events ; 0. 9 [95 % CI, 0. 6-1. 2] vs 0. 5 [95 % CI, 0. 3-0. 8] events per 100 person-years ; P =. 04).